Astronomical science or astronomical marketing?

Clinical Geriatrics

Volumn 17, Issue 11, 2009, Pages 36-

  Whayne Jr , Thomas F ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN;

CLINICAL RESEARCH; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG INDUSTRY; DRUG MEGADOSE; DRUG POTENCY; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MYOPATHY; NOTE; PROGNOSIS;

EID: 73149112398     PISSN: 10951598     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207. Published Online: November 9, 2008.
2. Wiviott SD, Cannon CP, Morrow DA, et al; PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: A PROVE IT-TIMI 22 substudy [published correction appears in J Am Coll Cardiol 2006;47(2):472]. J Am Coll Cardiol 2005; 46(8):1411-1416.
3. Jones PH, Davidson MH, Stein EA, et al; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152-160.
4. Sager PT, Melani L, Lipka L, et al; Ezetimibe Study Group. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003;92:1414-1418.
5. Thompson PD, Clarkson P, Karas RH. Statinassociated myopathy. JAMA 2003;289:1681-1690.